Perspective Therapeutics (NYSE:CATX) Upgraded at Cantor Fitzgerald

Perspective Therapeutics (NYSE:CATX) was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

CATX has been the topic of several other reports. UBS Group assumed coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target on the stock. Wedbush reiterated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Friday, January 24th. Bank of America downgraded Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. Oppenheimer reduced their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, November 22nd. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $16.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $15.14.

Perspective Therapeutics Trading Up 5.7 %

Perspective Therapeutics stock opened at $3.54 on Wednesday. Perspective Therapeutics has a twelve month low of $2.70 and a twelve month high of $19.05. The company has a 50 day moving average of $3.50 and a 200-day moving average of $9.30.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The business had revenue of $0.37 million during the quarter. As a group, analysts anticipate that Perspective Therapeutics will post -0.88 EPS for the current fiscal year.

Insider Transactions at Perspective Therapeutics

In other news, CFO Jonathan Robert Hunt acquired 12,829 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were acquired at an average cost of $3.82 per share, with a total value of $49,006.78. Following the completion of the purchase, the chief financial officer now directly owns 48,800 shares of the company’s stock, valued at $186,416. The trade was a 35.66 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Johan M. Spoor bought 8,000 shares of Perspective Therapeutics stock in a transaction on Wednesday, December 4th. The stock was acquired at an average cost of $3.77 per share, for a total transaction of $30,160.00. Following the acquisition, the chief executive officer now owns 36,257 shares in the company, valued at approximately $136,688.89. This represents a 28.31 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 67,570 shares of company stock valued at $256,789. 3.52% of the stock is currently owned by company insiders.

Institutional Trading of Perspective Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CATX. nVerses Capital LLC bought a new position in Perspective Therapeutics during the 3rd quarter worth $57,000. US Bancorp DE increased its position in shares of Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after buying an additional 3,866 shares during the period. Y Intercept Hong Kong Ltd bought a new position in Perspective Therapeutics during the fourth quarter worth $33,000. Intech Investment Management LLC acquired a new position in Perspective Therapeutics in the third quarter valued at $137,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Perspective Therapeutics during the third quarter valued at $152,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.